Published in final edited form as:

Curr Obstet Gynecol Rep. ; 1(3): 116–123. doi:10.1007/s13669-012-0014-7.

The Role of Endocrine Disruptors in the Epigenetics of Reproductive Disease and Dysfunction: Potential Relevance to Humans

Kaylon L. Bruner-Tran, PhD, David Resuehr, PhD, Tianbing Ding, PhD, John A. Lucas, MD, and Kevin G. Osteen, PhD

Women's Reproductive Health Research Center, Department of Obstetrics & Gynecology
Vanderbilt University School of Medicine, Nashville, TN, USA 37232

Abstract

In a murine model, we have linked early life toxicant exposure to reduced uterine sensitivity to progesterone, a phenotype we had previously associated with inflammation in endometriosis patients. Subsequent studies revealed that developmental toxicant exposure not only reduces fertility in male and female mice but also negatively impacts pregnancy leading to spontaneous preterm birth (PTB). An epigenetic alteration of the progesterone receptor gene correlated with reduced fertility and adverse pregnancy outcomes and persisted in multiple generations of mice in the absence of an additional toxicant exposure. Gene-environment interactions in women may explain why some patients “at risk” for PTB deliver at term while others without known risks deliver early. Our model provides a unique system to unravel the interactive influences of inflammation and reduced progesterone responsiveness on PTB and suggests that therapy needs to begin prior to pregnancy (and involve both partners) rather than once the inflammatory cascade has been initiated.

Introduction

The primary biological role of the human uterus is to provide a supportive in vivo environment for optimum fetal growth and development prior to live birth. Despite this singular purpose, coordination of the initiation and maintenance of pregnancy within the uterus requires a complex interplay between the maternal endocrine and immune systems, the paternally-derived placenta and the fetus itself. Cellular communication missteps at the interface of these two systems within the uterus can result in infertility, pregnancy loss or preterm birth (PTB). A significant impediment to therapeutically improving fertility and avoiding adverse pregnancy outcomes is our imperfect understanding of key elements of uterine function during each interval of human gestation as a consequence of ethical considerations which limit direct studies. Nevertheless, it is well-known that the establishment and maintenance of pregnancy are progesterone dependent processes; thus defects in the production or action of this steroid, as a result of environmental stressors or an

individual's genetic or epigenetic predisposition, can undermine pregnancy success. Additionally, a growing body of evidence suggests that reproductive tract diseases and dysfunction may be a consequence of a previous exposure to bioactive chemical contaminants capable of inducing epigenetic alterations [1–5]. The potential that epigenetic alterations in either the male or female germline may continue to negatively affect reproductive health for multiple generations suggest an urgent need to better understand the mechanisms and functional impact of toxicant-mediated cellular changes so that appropriate therapeutic intervention strategies can be developed. To address this challenge, our translational research group has explored the mechanisms by which TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) may negatively influence progesterone action related to the development of endometriosis, a common reproductive disorder affecting fertility and pregnancy outcomes in women worldwide.

Endometriosis, the presence of endometrial glands and stroma outside the uterus, remains one of the most poorly understood conditions affecting not only women's reproductive potential, but their overall quality of life. Significantly, the human endometrium is an important component of the mucosal immune system; thus coordination between the endocrine and immune systems is critical for successful pregnancy. Consequently, disruptions in cell-cell communication affecting the interface of the endocrine and immune systems within the reproductive tract are likely sentinel, inflammation-related events in the development of endometriosis and other reproductive disorders. Specifically, we have shown that the loss of endometrial progesterone sensitivity, a well-recognized component of endometriosis, is biologically linked to an inflammatory-like pattern of cell-cell communication within the uterus [6–8]. Importantly, altered patterns of cell-cell communication likely impact other areas of the reproductive tract in women with endometriosis, potentially compromising pregnancy success [9]. Whether reduced reproductive tract responsiveness to progesterone leads to the development of endometriosis or emerges as a consequence of the inflammatory nature of the disease is currently unknown. Nevertheless, once in place, a loss in the differentiation promoting, anti-inflammatory actions of progesterone would be expected to functionally compromise numerous aspects of reproductive success [10]. While reduced fertility has long been associated with endometriosis (see [11] for review), the anti-inflammatory action of progesterone is equally critical for the maintenance of pregnancy; thus it is not surprising that fertile women with this disease also possess an increased risk of delivering preterm [12].

Environmental Endocrine Disruptors in Reproduction

Critical and currently unresolved questions related to environmental disruption of progesterone-mediated reproductive success are: what are the trigger mechanisms leading to progesterone resistance in the adult reproductive tract and when are these triggers activated? For example, in co-cultures of stromal and epithelial cells acquired from the endometrium of disease-free adult donors, we have shown that short term exposure to TCDD triggers an inflammatory-like pattern of cell-cell communication that reduces the stromal cell expression of the progesterone receptor-B (PR-B) isotype [13]. In turn, blocking this inflammatory-like pattern of stromal-epithelial communication in similar human endometrial cultures treated, prevented the TCDD-mediated loss of PR expression [14].

However, our capacity to detoxify TCDD and other toxicants as adults is much greater than our early life capacity to limit the impact of similar exposures [15]. Human exposure to environmental toxicants begins in utero, continues throughout our adult reproductive lives and some chemically stable, fat soluble toxicants accumulate in our bodies. As will be discussed below, a transfer of the potentially negative influence of environmental toxicants can occur indirectly via epigenetic alterations which can be propagated across multiple generations [1, 4–5]. Thus, it is important to ascertain the relative risk of environmental toxicant exposures across an individual's lifetime in order to understand the origin(s) of the reduced progesterone sensitivity observed in the reproductive tract of endometriosis patients.

Numerous chemicals, both natural and manufactured, may act as disruptors of endocrine and immune system development during critical periods of gene programming, potentially compromising not only adult reproductive health [16] but also promoting cancer, and diabetes-related obesity [17]. It is estimated that more than 80,000 chemicals have been released into our environment within the United States over the past few decades and current regulations do not require prospective risk assessment of these multiple, potentially interactive chemicals on human health [18]. Thus, a significant challenge to the study of environmental toxicants that may disrupt human reproductive health is the initial choice of an individual toxicant for study. Our choice of TCDD as a prototypical endocrine/immune disrupting toxicant for our studies reflects the well-established toxicity and high affinity binding characteristics of this compound to the aryl hydrocarbon receptor (AhR). The AhR, an orphan nuclear receptor, is abundantly expressed within human and murine reproductive tissues [19–20]. A number of environmental endocrine disruptors produced by industrial processes and/or present in cigarette smoke bind this receptor and disrupt reproductive processes across multiple species [21].

TCDD and other polychlorinated dibenzo-p-dioxins, generally called dioxins, are members of a family of chlorinated aromatic hydrocarbons that accumulate as ubiquitous contaminants in our environment; thus ingestion of contaminated food is the primary source of human exposure [22–24]. TCDD is considered to be the most toxic dioxin congener and has been shown to disrupt steroid receptor levels, metabolism and transport [25–27]. Significantly, TCDD and dioxin-like PCBs (polychlorinated biphenyls) readily cross the placenta and accumulate in breast tissue, allowing exposure of the fetus during pregnancy and the neonate during lactation [28]. Within our human and rodent toxicology studies, we utilized TCDD as a research tool to specifically define critical elements of steroid-mediated cell and tissue function within the reproductive tract that may be susceptible to disruption by environmental toxicants with dioxin-like action. Since progesterone plays an absolutely critical role in stabilizing the maternal-fetal interface in support of pregnancy, we focused our rodent work on the ability of TCDD to disrupt the anti-inflammatory action of progesterone during gestation. As discussed below, we have linked developmental toxicant exposure of female mice to reduced fertility and an elevated risk of PTB for multiple generations [4] while a similar toxicant exposure of male mice also leads to adverse reproductive outcomes [29–30]. Given the findings of our rodent model and others as noted above, it would be prudent to consider the possibility that early life environmental exposures in women might lead to epigenetic modifications that negatively affect adult reproductive tract function.

Basic Epigenetic Mechanisms

For over half a century, human genetics research has focused on DNA as the heritable molecule responsible for carrying phenotypic information from the parent to the offspring. Changes in phenotype would, according to this paradigm, underlie changes in DNA sequence due to mutations in single genes or a small number of genes. However, epigenetic marking of DNA is now recognized as an important mechanism by which gene expression can be altered without a change to the DNA sequence. Although these marks are not necessarily permanent, they are stable and inheritable [31–32] and thus, in addition to genetic mutations, epigenetic modifications also contribute to an individual's overall appearance, reproductive capacity and susceptibility to disease. During development, many cells undergo reprogramming, in which epigenetic marks are removed and new ones acquired, resulting in cellular differentiation along a particular path within each organ system despite the presence of identical DNA. In this manner, epigenetic modifications determine a cell's destiny and the unique phenotypic and functional characteristics of specific tissues and organs. Within the differentiated somatic cells of adults, epigenetic modifications accumulate as we age, and are in large part, the reason we “get old” and become more susceptible to certain (age-related) diseases. Nevertheless, although epigenetic marks can be acquired over an individual's lifetime, these changes do not usually affect the phenotype of the next generation. In contrast, environmental factors that affect epigenetic marks within the germ line can be inherited and have the potential to contribute to an offspring's phenotype [33].

The primary role of epigenetic modification is to control DNA accessibility, i.e. the ability of the cellular machinery to switch genes on, thereby activating transcription. The best described mechanisms of epigenetic changes are methylation and acetylation of DNA and histones [34]. Hypermethylation of DNA is generally associated with gene silencing while hyperacetylation of histones leads to chromatin relaxation and unwinding which promotes gene transcription. DNA can be methylated at cytosine residues, frequently within the promoter regions of specific genes, but also within distal regions of DNA that together contribute to epigenetic regulation [35–36]. DNA methylation can down regulate gene transcription by physically impeding the binding of transcription factors to the promoter or by enhancing the binding of methyl-CpG-binding domain proteins (MBDs) to DNA which leads to the formation of compact, inactive heterochromatin. Epigenetic modifications can also target histones which impact DNA accessibility. At the chromatin level, histones, can be covalently modified via acetylation, phosphorylation, methylation, ubiquitination, sumoylation or ADP ribosylation or combinations of these mechanisms. Hyperacetylation of chromatin proteins leads to open DNA and transcriptional activation while histone deacetylation leads to gene silencing. Residing in the genome of normal cells within various organ systems there are “healthy” patterns of methylation and acetylation which appropriately regulate the transcription of certain genes. Not surprisingly, the presence of aberrant epigenetic patterns can cause developmental abnormalities and are associated with the etiology of certain human diseases [37] in addition to the reproductive failures discussed herein.

Thus, in addition to information present within an individual's specific genetic code (DNA sequence), epigenetic alterations can modulate how this otherwise hard-wired genetic information is utilized within a cell. Significantly, although such epigenetic changes are stable, they are themselves also subject to modification. Specifically, while lifestyle choices such as smoking can promote epigenetic changes which effectively accelerate aging, epigenetic therapies are also being designed which can reverse these changes in order to combat certain cancers and other diseases [38–40]. For most couples, developing lifestyle choices that preserve a healthy epigenome may dramatically reduce not only their individual disease susceptibility but may promote the long term health of their future offspring [41–43].

Evidence for Early Life Origins of Reproductive Dysfunction in a Mouse Model

As noted above, the environmental endocrine disruptor TCDD was selected as a “prototypical toxicant” for our reproductive toxicology studies based on several rodent, primate and human studies that associated chemicals with dioxin-like action to the development of endometriosis (reviewed by [6]). Our initial studies utilized human endometrial cell culture models for analysis of cellular responses to acute TCDD exposure and an in vivo chimeric model of human experimental endometriosis in immunocompromised mice. This dual approach allowed us to demonstrate that acute, in vitro TCDD exposure was associated with the development of a progesterone-resistant endometrial cell phenotype which promoted establishment of an endometriotic-like experimental disease [13, 44]. We additionally demonstrated that acute TCDD exposure of human endometrial tissues disrupted the anti-inflammatory action of progesterone and led to an increase in endometrial tissue sensitivity to inflammatory cytokines, a toxicant-mediated response that increased the secretion of matrix metalloproteinases (MMPs) and promoted the invasive potential of endometrial tissue in our chimeric experimental endometriosis model (reviewed by [44–45]).

The laboratory-based studies noted above and similar studies using adult cells and tissues suggest that TCDD-mediated activation of the endometrial MMP system may represent a key mechanistic pathway linking toxicant exposure to the invasive establishment of endometriosis [6]. However, as opposed to experimental evidence, epidemiologic studies attempting to associate endometriosis with adult body burdens of dioxin-like environmental toxicants in various human populations remain inconclusive (reviewed by [6, 46]). Perhaps explaining this discrepancy, humans and other mammals are most sensitive to environmental toxicant exposure during their development and current epidemiology studies attempting to link adult body burdens to a current disease status does not adequately consider the potential impact of early life exposures. Thus, in addition to human population studies, appropriate animals models are needed to examine the potential biochemical and functional effects of toxicant exposure during the in utero/early neonatal period that may negatively impact future reproductive outcomes. It is not possible to design an animal-based research strategy that duplicates complex human population exposure paradigms or the genetic variability among individuals. However, it is quite possible to utilize an early life toxicant exposure

model in mice as a discovery tool to identify specific cellular and molecular signaling defects that may be equally involved in infertility and adverse pregnancy outcomes in humans. In particular, we designed our studies to explore whether an early life TCDD exposure would subsequently lead to an adult uterine phenotype that exhibited the reduced uterine progesterone response and heightened sensitivity to inflammation that our past in vitro studies had identified.

Within our studies, pregnant 10–12 wk old female C57BL/6 mice (F0, or founding generation) are exposed to TCDD (10µg/kg) by gavage on embryonic day 15.5 (E15.5), when organogenesis is complete, similar to approaches used by previous investigators [47–48]. This level of experimental TCDD exposure during late pregnancy is not teratogenic or abortigenic, reflects the rapid clearance of this toxicant in mice and is well below the LD₅₀ for this strain (230µg/kg) [49]. Using this model, we reported that early life/in utero exposure of female mice to TCDD leads to an adult uterine phenotype in animals which mimics the reduced uterine progesterone responsiveness observed in women with endometriosis [50]. However, mating studies involving offspring from our exposure model revealed a reduced reproductive capacity in both male and female (F1) mice, with adult animals exhibiting a variety of reproductive phenotypes, similar to the human spectrum. Specifically, as shown in Table 1 within each litter, some male and female mice exhibit infertility at sexual maturity while other animals exhibit normal fertility when mated to an unexposed partner. Among mating pairs of mice achieving pregnancy, a relatively high rate of spontaneous PTB was also observed [4, 29]. Again, reflecting our in vitro findings following acute exposure of human endometrial cells and tissues to TCDD, the occurrence of PTB in toxicant exposed F1 female mice occurred coincident with the phenotype of reduced uterine progesterone responsiveness and heightened sensitivity to inflammatory signals during pregnancy [4, 29]. An interesting and somewhat unexpected finding was that, among fertile F1 males, we documented a significant rate of PTB following matings to unexposed female partners concomitant with premature placental inflammation [29–30]. Furthermore, in the absence of additional toxicant exposures, diminished fertility and an increased risk of PTB was observed in descendants of either male or female F1 mice (Table 1).

Our findings of both infertility and PTB in our murine model of early life TCDD exposure are perhaps not unexpected since the phenotype of the F1-F3 female animals reflects the uterine phenotype of women with endometriosis [50]. Certainly, recent human studies in cohorts of women with endometriosis have shown that these patients possess an increased risk for PTB [12, 51] as our murine model predicted [4, 6]. However, a novel aspect of our animal model, not previously recognized in most human studies, is that the early life/in utero toxicant exposure history of either parent to TCDD may impact PTB by disrupting progesterone-mediated patterns of cell-cell communication at the maternal-fetal interface [29]. In this regard, a central finding of each of our human and murine studies to date is that the ability of TCDD exposure to disrupt the anti-inflammatory action of progesterone and subsequently increase the reactivity of cells and tissues within the reproductive tract to pro-inflammatory signals. The importance of this central observation to reproductive success emerged when we observed a doubling of the PTB rate in response to infection-related inflammation during a pregnancy study in F1 females. Following an unexpected parvovirus

(MPV) outbreak in our colony, 86% of pregnant female F1 mice and 67% of F3 female mice delivered preterm compared to 37% and 25%, respectively, in similar studies conducted in the absence of MPV [4]. Importantly, control, pregnant mice housed within the same colony never delivered preterm, even during the MPV outbreak [4]. This serendipitous finding suggests that the TCDD mediated decrease in progesterone responsiveness may have only a modest impact on length of pregnancy in the absence of an additional stressor. To confirm the dual-hit etiology for increased PTB in our model, we conducted a follow-up study using a very low dose of LPS (lipopolysaccharide; 200 ug/kg), which does not induce PTB in control animals of the same strain. As predicted, while none of our control mice exhibited PTB following exposure to our low-dose LPS paradigm, PTB was observed in 100% of female mice with a history of direct (F1) or ancestral (F3) exposure to TCDD (Table 2). While a similar human study would not be possible, our murine study clearly indicates that increased sensitivity to inflammation is one mechanism by which early life toxicant-exposure may lead to an increased risk of PTB at sexual maturity.

Our data, demonstrating reduced fertility in both sexes and increased risks of PTB in female mice across multiple generations following a single, developmental exposure to TCDD strongly suggests toxicant mediated epigenetic modifications have occurred. In order to more closely examine the potential epigenetic consequence of developmental TCDD exposure, we examined the methylation status of the PR gene in uterine samples from our female mice. As discussed above, DNA hypermethylation can mediate gene silencing and is an important mechanism by which inheritable epigenetic modifications may occur [33]. Our in vitro toxicant exposure studies demonstrated that TCDD-associated suppression of PR-B gene and protein expression may be mediated by the local action of toxicant-induced inflammatory cytokines [13–14]. Additionally, Wu et al [52] demonstrated that treatment of isolated human endometrial epithelial cells with TNF- α led to hypermethylation of the PR promoter and a loss of PR-B protein expression. Taken together, these in vitro human cell data suggested to us that the loss of progesterone sensitivity associated with developmental exposure of mice to TCDD may be due to an epigenetic modification, mediated by inflammatory processes. As shown in Figure 1, examination of murine uteri by methylation-specific PCR (MS-PCR) revealed partial methylation of the PR in 60% of tissues removed from F1 females (exposed to TCDD in utero) while this gene was largely unmethylated in similar tissue samples acquired from control mice. In order to determine if PR gene hypermethylation is a transient or stable (inheritable) effect, we similarly examined tissues removed from F3 females (the “granddaughters” of F1 mice). As shown in Figure 1, 40% of F3 animals also exhibit partial methylation of the PR gene, suggesting that the transgenerational infertility phenotype and associated risk of PTB in these animals may be due to epigenetic modifications as a consequence of ancestral TCDD exposure.

Clinical Perspective

Our emerging appreciation that many diseases and conditions affecting adults are influenced by the prevailing in utero microenvironment [16] suggests that reproductive health may also be negatively influenced by disruption of normal fetal development. Within this review, we have discussed our previous human studies related to endometriosis as well as recent experimental findings in a murine model that demonstrates an epigenetic link between early

life exposure to TCDD and the development of reduced progesterone sensitivity within the reproductive tract across multiple generations. Our studies also uncovered a novel role for male exposure to environmental toxicants on reproductive outcomes in their female partners. Clearly, prospective reproductive toxicology studies cannot be conducted in pregnant women or women seeking pregnancy and linking a couple's past environmental exposure histories affecting reproductive potential is difficult. Nevertheless, our murine studies suggest that couples may be "at risk" for both infertility and PTB as a consequence of the environmental exposures of their parents and grandparents. For example, within our animal colony, mice with direct or ancestral TCDD exposure exhibited a heightened sensitivity to exogenous inflammatory stimuli (MPV or LPS) which further affected the anti-inflammatory action of progesterone sensitivity and the related risk of PTB (Table 2). Animals without toxicant exposure never exhibited these phenotypic changes related to PTB, despite also being exposed to MPV or LPS. Although intrauterine infections have been identified in only about 1/3 of PTBs, sophisticated methodology has demonstrated the presence of bacteria in up to 70% of women undergoing elective cesarean section at term [53]. These human data strongly suggest that the presence of bacteria alone is not sufficient to cause PTB in most women. Our results in mice, suggest another necessary contributor to PTB might be a maladaptive inflammatory response within the reproductive tract related to changes in progesterone sensitivity. Thus various stressors encountered during the course of most pregnancies (viruses, bacteria or even emotional stress) may each represent a more significant risk factor for adverse outcomes in women with altered sensitivity to progesterone, perhaps amplified by a prior environmental toxicant exposure.

Certainly, the transgenerational studies presented within this review suggest that the toxicant exposure/adult disease relationship can become disassociated not only across an individual's lifespan but across multiple generations. This temporal dissociation suggests that a patient presenting with infertility or history of PTB may have no identifiable risk factors, yet she may still be at risk as a consequence of her ancestry or that of her partner. Given these confounders and the difficulty in obtaining an accurate exposure history within a clinical setting, a more logical approach may be to presume that most patients and their partners have a history of toxicant exposure (as a consequence of living in an industrialized country). In this regard, excess or inappropriate inflammation appears to be a recurring theme that contributes to the development of both reduced fertility and adverse pregnancy outcomes in our murine model. Thus, a strategy that assumes that a woman's individual sensitivity to various triggers of inflammation may be adversely affecting her reproductive outcomes could include dietary intervention in both the male and female partner using clinically acceptable therapies that would do no harm if the assumption of toxicant exposure is erroneous.

Omega-3 fatty acids are well-recognized as anti-inflammatory agents and have been suggested to reduce the risk of PTB in some but not all human studies [54–55]. The finding of only a modest increase in gestational length may be due to the timing of current human therapy initiation (20 weeks and beyond) and the lack of consideration of the contribution of the male to adverse pregnancy outcomes. In our experimental model in mice, we have explored the impact of an omega-3 enriched diet in adult male animals with a known toxicant exposure history prior to initiation of pregnancy in an unexposed female partner.

Our strategy was to introduce a preconception diet in male animals that would potentially reduce the inflammatory phenotype of the paternally-derived placenta that we had previously associated with the risk of PTB [29]. Using this approach, we successfully prevented PTB in control female mice mated to F1 males provided a fish oil supplemented diet for the two weeks preceding mating [30]. At this juncture, we have not yet determined if the improved pregnancy outcomes associated with the supplemented diet was mediated by a change in the inflammatory epigenome of the placenta or simply a consequence of preserving the anti-inflammatory action of progesterone at the maternal-fetal interface. Nevertheless, a similar nutritional, anti-inflammatory approach in humans may be an appropriate clinical choice with regard to promoting fertility and protecting pregnancy without compromising the health of the patients and should be beneficial to the post-natal health of the offspring even in the absence of a readily identifiable need for intervention.

Conclusion

In summary, our initial human studies with TCDD were designed to explore the role of inflammation in the loss of progesterone sensitivity that had been identified as a key component in the pathophysiology of endometriosis (reviewed by [14]). In turn, we developed our murine model to determine whether an early life toxicant exposure may lead to the development of the progesterone-resistant reproductive tract phenotype associated with this disease [50]. It is perhaps not surprising that the pregnancy studies we conducted in our toxicant exposure model suggested that the endometriosis-like phenotype not only affects fertility in female mice but also impacts their pregnancy outcomes [4]. Our murine model provided us with an unexpected experimental system to unravel the influence of reduced progesterone responsiveness on the various etiologies of PTB that have been identified in humans that directly or indirectly relate to inflammation. The superimposition of any number of well recognized risk factors for PTB (e.g. infection, socio-economic position, stress, etc.) upon a maladaptive inflammatory phenotype would be expected to trigger the cascade of the final common pathway leading to PTB. Clinical translation of the murine studies described herein would suggest that human therapy should shift fundamentally from abatement once the inflammatory cascade is set in motion (tocolytics, supplemental progesterone) to a preemptive interventional strategy involving both partners in order to restore homeostasis in the pro-inflammatory/anti-inflammatory balance prior to the onset of pregnancy.

Acknowledgments

This work was supported by NIEHS ES14942; NCCAM AT006245 and *The Endometriosis Association*.

References

1. Anway MD, et al. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science*. 2005; 308(5727):1466–9. [PubMed: 15933200]
2. Taylor HS. Endocrine disruptors affect developmental programming of HOX gene expression. *Fertil Steril*. 2008; 89(2 Suppl):e57–8. [PubMed: 18308065]
3. Newbold RR. Developmental exposure to endocrine-disrupting chemicals programs for reproductive tract alterations and obesity later in life. *Am J Clin Nutr*. 2011; 94(6 Suppl):1939S–1942S. [PubMed: 22089436]

4. Bruner-Tran KL, Osteen KG. Developmental exposure to TCDD reduces fertility and negatively affects pregnancy outcomes across multiple generations. *Reprod Toxicol*. 2011; 31(3):344–50. [PubMed: 20955784]
- 5● Manikkam M, et al. Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures. *PLoS One*. 2012; 7(2):e31901. [PubMed: 22389676] ● This study compared the differing influence of multiple toxicants on epigenetic transgenerational inheritance in developmentally exposed male and female rats. Results indicate that a variety of compounds are capable of inducing epigenetic changes which influence the phenotype across multiple generations.
6. Bruner-Tran KL, Ding T, Osteen KG. Dioxin and endometrial progesterone resistance. *Semin Reprod Med*. 2010; 28(1):59–68. [PubMed: 20104429]
7. Bruner-Tran KL, et al. Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. *J Clin Endocrinol Metab*. 2002; 87(10):4782–91. [PubMed: 12364474]
8. Bruner-Tran KL, et al. Down-regulation of endometrial matrix metalloproteinase-3 and -7 expression in vitro and therapeutic regression of experimental endometriosis in vivo by a novel nonsteroidal progesterone receptor agonist, tanaproget. *J Clin Endocrinol Metab*. 2006; 91(4):1554–60. [PubMed: 16418212]
9. Herington JL, et al. Immune interactions in endometriosis. *Expert Rev Clin Immunol*. 2011; 7(5): 611–26. [PubMed: 21895474]
10. Osteen KG, Bruner-Tran KL, Eisenberg E. Reduced progesterone action during endometrial maturation: a potential risk factor for the development of endometriosis. *Fertil Steril*. 2005; 83(3): 529–37. [PubMed: 15749474]
11. Bulun SE. Endometriosis. *N Engl J Med*. 2009; 360(3):268–79. [PubMed: 19144942]
12. Harkki P, Tiitinen A, Ylikorkala O. Endometriosis and assisted reproduction techniques. *Ann N Y Acad Sci*. 2010; 1205:207–13. [PubMed: 20840274]
13. Igarashi TM, et al. Reduced expression of progesterone receptor-B in the endometrium of women with endometriosis and in cocultures of endometrial cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Fertil Steril*. 2005; 84(1):67–74. [PubMed: 16009159]
14. Bruner-Tran KL, et al. Dioxin may promote inflammation-related development of endometriosis. *Fertil Steril*. 2008; 89(5 Suppl):1287–98. [PubMed: 18394613]
15. Landrigan PJ, Suk WA, Amler RW. Chemical wastes, children's health, and the Superfund Basic Research Program. *Environ Health Perspect*. 1999; 107(6):423–7. [PubMed: 10339440]
16. Heindel JJ. Role of exposure to environmental chemicals in the developmental basis of reproductive disease and dysfunction. *Semin Reprod Med*. 2006; 24(3):168–77. [PubMed: 16804815]
17. Hanson MA, Low FM, Gluckman PD. Epigenetic epidemiology: the rebirth of soft inheritance. *Ann Nutr Metab*. 2011; 58(Suppl 2):8–15. [PubMed: 21846977]
18. National Toxicology Program. 2001. Available from: <http://ntp-server.niehs.gov/htdocs/liason/LowDosePeerFinalRpt.pdf> Accessed February, 2012
19. Bofinger DP, et al. Effect of TCDD exposure on CYP1A1 and CYP1B1 expression in explant cultures of human endometrium. *Toxicol Sci*. 2001; 62(2):299–314. [PubMed: 11452143]
20. Nayyar, T.; Bruner-Tran, KL.; Osteen, K. Developmental Dioxin and Endometriosis. In: Gupta, R., editor. *Developmental Reproductive Toxicity*. Academic Press/Elsevier; 2011.
21. Birnbaum LS. Evidence for the role of the Ah receptor in response to dioxin. *Prog Clin Biol Res*. 1994; 387:139–54. [PubMed: 7972244]
22. Harrad S, et al. Human dietary intake and excretion of dioxin-like compounds. *J Environ Monit*. 2003; 5(2):224–8. [PubMed: 12729259]
23. Pompa G, Caloni F, Fracchiolla ML. Dioxin and PCB contamination of fish and shellfish: assessment of human exposure. Review of the international situation. *Vet Res Commun*. 2003; 27(Suppl 1):159–67. [PubMed: 14535384]
24. Schecter A, et al. Dioxins in commercial United States baby food. *J Toxicol Environ Health A*. 2002; 65(23):1937–43. [PubMed: 12490040]

25. Heimler I, et al. Dioxin perturbs, in a dose- and time-dependent fashion, steroid secretion, and induces apoptosis of human luteinized granulosa cells. *Endocrinology*. 1998; 139(10):4373–9. [PubMed: 9751521]
26. Moran FM, et al. Molecular target of endocrine disruption in human luteinizing granulosa cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin: inhibition of estradiol secretion due to decreased 17alpha-hydroxylase/17,20-lyase cytochrome P450 expression. *Endocrinology*. 2003; 144(2):467–73. [PubMed: 12538606]
27. Pocar P, et al. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. *Reproduction*. 2005; 129(4):379–89. [PubMed: 15798013]
28. Suzuki G, Nakano M, Nakano S. Distribution of PCDDs/PCDFs and Co-PCBs in human maternal blood, cord blood, placenta, milk, and adipose tissue: dioxins showing high toxic equivalency factor accumulate in the placenta. *Biosci Biotechnol Biochem*. 2005; 69(10):1836–47. [PubMed: 16244432]
29. Ding T, et al. Developmental dioxin exposure of either parent is associated with an increased risk of preterm birth in adult mice. *Reprod Toxicol*. 2011; 31(3):351–8. [PubMed: 21093581]
30. McConaha ME, et al. Preconception omega-3 fatty acid supplementation of adult male mice with a history of developmental 2,3,7,8-tetrachlorodibenzo-p-dioxin exposure prevents preterm birth in unexposed female partners. *Reproduction*. 2011; 142(2):235–41. [PubMed: 21653731] ●
Using a mouse model, this study examined the influence of a paternal preconception diet supplemented with fish oil to suppress toxicant-associated placental inflammation at the end of pregnancy; thereby preventing preterm birth.
31. Gabory A, Attig L, Junien C. Epigenetic mechanisms involved in developmental nutritional programming. *World J Diabetes*. 2011; 2(10):164–75. [PubMed: 22010058]
32. Morgan HD, et al. Epigenetic reprogramming in mammals. *Hum Mol Genet*. 2005; 14:R47–58. Spec No 1. [PubMed: 15809273]
33. Guerrero-Bosagna C, Skinner MK. Environmentally induced epigenetic transgenerational inheritance of phenotype and disease. *Mol Cell Endocrinol*. 2012; 354(1–2):3–8. [PubMed: 22020198]
34. Choo KB. Epigenetics in disease and cancer. *Malays J Pathol*. 2011; 33(2):61–70. [PubMed: 22299205]
35. Casas-Delucchi CS, Cardoso MC. Epigenetic control of DNA replication dynamics in mammals. *Nucleus*. 2011; 2(5):370–82. [PubMed: 21983084]
36. Martin C, Zhang Y. Mechanisms of epigenetic inheritance. *Curr Opin Cell Biol*. 2007; 19(3):266–72. [PubMed: 17466502]
37. Jiang YH, et al. A mixed epigenetic/genetic model for oligogenic inheritance of autism with a limited role for UBE3A. *Am J Med Genet A*. 2004; 131(1):1–10. [PubMed: 15389703]
38. Hagelkruys A, et al. The biology of HDAC in cancer: the nuclear and epigenetic components. *Handb Exp Pharmacol*. 2011; 206:13–37. [PubMed: 21879444]
39. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. *Curr Med Chem*. 2011; 18(11):1658–71. [PubMed: 21428881]
40. Xu K, et al. Targeting HDACs: a promising therapy for Alzheimer's disease. *Oxid Med Cell Longev*. 2011; 2011:143269. [PubMed: 21941604]
41. Alegria-Torres JA, Baccarelli A, Bollati V. Epigenetics and lifestyle. *Epigenomics*. 2011; 3(3):267–77. [PubMed: 22122337]
42. Gallou-Kabani C, et al. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. *Clin Chem Lab Med*. 2007; 45(3):321–7. [PubMed: 17378726]
43. Li CC, et al. Epigenetic programming by maternal nutrition: shaping future generations. *Epigenomics*. 2010; 2(4):539–49. [PubMed: 22121973]
44. Bruner-Tran KL, et al. The potential role of environmental toxins in the pathophysiology of endometriosis. *Gynecol Obstet Invest*. 1999; 48(Suppl 1):45–56. [PubMed: 10559664]
45. Bruner-Tran, KL.; McConaha, M.; Osteen, K. Models of Endometriosis: Animal Models. In: Giudice, L.; Evers, JL.; Healy, J., editors. *Endometriosis: Science and Practice*. Wiley-Blackwell Publishing; 2011.

46. Anger DL, Foster WG. The link between environmental toxicant exposure and endometriosis. *Front Biosci.* 2008; 13:1578–93. [PubMed: 17981650]
47. Besteman EG, et al. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or diethylstilbestrol (DES) cause similar hematopoietic hypocellularity and hepatocellular changes in murine fetal liver, but differentially affect gene expression. *Toxicol Pathol.* 2007; 35(6):788–94. [PubMed: 17943652]
48. Lawrence BP, Vorderstrasse BA. Activation of the aryl hydrocarbon receptor diminishes the memory response to homotypic influenza virus infection but does not impair host resistance. *Toxicol Sci.* 2004; 79(2):304–14. [PubMed: 14976337]
49. Vogel CF, Matsumura F. Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) with induced adipocyte differentiation in mouse embryonic fibroblasts (MEFs) involves tyrosine kinase c-Src. *Biochem Pharmacol.* 2003; 66(7):1231–44. [PubMed: 14505802]
50. Nayyar T, et al. Developmental exposure of mice to TCDD elicits a similar uterine phenotype in adult animals as observed in women with endometriosis. *Reprod Toxicol.* 2007; 23(3):326–36. [PubMed: 17056225]
51. Brosens I, et al. Risks of adverse pregnancy outcome in endometriosis. *Fertil Steril.* 2012
52. Wu Y, et al. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. *Epigenetics.* 2006; 1(2):106–11. [PubMed: 17965625]
53. Steel JH, et al. Bacteria and inflammatory cells in fetal membranes do not always cause preterm labor. *Pediatr Res.* 2005; 57(3):404–11. [PubMed: 15659699]
54. Jordan RG. Prenatal omega-3 fatty acids: review and recommendations. *J Midwifery Womens Health.* 2010; 55(6):520–8. [PubMed: 20974414]
55. McGregor JA, et al. The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcomes. *Obstet Gynecol Surv.* 2001; 56(5 Suppl 1):S1–13. [PubMed: 11333379]

Figure 1. Methylation Specific PCR of the progesterone receptor

Methylation Specific PCR of the progesterone receptor of whole uterine samples obtained from control, F1 or F3 female mice. Extracted DNA was subjected to bisulfite conversion and real-time PCR using methylation-specific primers and standard methodology (Wu et al, 2006). N = 5 for all groups.

Table 1

Impact of Developmental TCDD Exposure on Transgenerational Reproductive Outcomes of Male and Female Mice

Mouse Exposure History generation	Pregnancy Rate *	Pregnancy Outcome	
		<i>Full-term</i>	<i>Preterm</i>
Vehicle Control	15/15 (100%)	15/15	0/15
TCDD <i>in utero</i>			
F1 female	15/36 (41%)	60	40
F3 female	10/17 (61%)	63	37
TCDD <i>in utero</i>			
F1 male	27/58 (46.5%)	67	33
F3 male	9/20 (45%)	78	22

* Most animals required multiple mating attempts to achieve pregnancy. Mice which did not achieve pregnancy following 4 positive vaginal plugs were considered infertile.

Table 2

Impact of Low Dose LPS Exposure in Mice with a Direct or Ancestral History of TCDD Exposure

Mouse History	Time to Delivery after LPS	
	<i>16hrs</i>	<i>at Term</i>
Control + PBS		100%
Control + LPS		100%
F1 female + LPS	100%	
F3 Female + LPS	100%	

N 6 per group.